Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies

Humans possess abundant amounts of microorganisms, including bacteria, fungi, viruses, and archaea, in their gut. Patients with nonalcoholic fatty liver disease (NAFLD) exhibit alterations gut microbiome an impaired barrier function. Preclinical studies emphasize the significance pathogenesis NAFLD. In this overview, we explore how adjusting could serve as innovative therapeutic strategy for We provide a summary current information on untargeted techniques such probiotics fecal microbiota transplantation, well targeted microbiome-focused therapies engineered prebiotics, postbiotics, phages treatment